Evaluation of Nasal Inflammatory Biomarkers

Inclusion Criteria

• •1. Able and willing to give written informed consent.
• •2. Male or female, age 18-65 years.
• •Women will be considered for inclusion if they are:
• •* Not pregnant, as confirmed by pregnancy test, and not nursing.
• •* Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchal, or post-menopausal with documented proof of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit).
• •* Of childbearing potential and using a highly effective method of contraception during the entire study, as defined by at least one of the following
• •* vasectomised partner
• •* sexual abstinence (the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to Visit 2 procedures until at least 72 hours after NAC)
• •* implants, injectables, combined oral contraceptives, hormonal IUDs or double-barrier methods (i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap)
• •3. History of seasonal allergic rhinitis to grass pollen with symptoms during the 2016 and 2017 allergen season requiring treatment with anti-histamines, nasal corticosteroids or leukotriene antagonists.
• •4. Absence of significant current symptoms of allergic rhinitis consistent with being out of season for their principal allergen (eg grass).
• •5. Skin prick test positive for mixed grass pollen allergen at Visit 1 or within one year prior to screening.